Entrar/Registro  
HOME SPANISH
 
Revista Alergia México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Revista Alergia México >Year 2009, Issue 4


Rubio-Padilla M, Río-Navarro BE, Hilda SN, Sienra-Monge JJL
Difficult-to-control asthma. A bibliographical review
Revista Alergia México 2009; 56 (4)

Language: Español
References: 34
Page: 115-123
PDF: 748.10 Kb.


Full text




ABSTRACT

Difficult-to-control asthma is a disease that causes serious exacerbations, near-fatal attacks, frequent hospitalizations, and needs chronic use of high doses of inhaled corticosteroids or daily oral corticosteroid therapy. On the basis of epidemiological studies, the risk factors for serious asthma are: female gender, high BMI, sensitivity to aspirin, gastro esophageal reflux, sinusitis, pneumonia history, and beginning of asthma symptoms in adult late age. It has been found that in severe asthma the inflammatory profile commonly changes with major participation of neutrophils, and evidence of destruction and remodelling. The first step in the care of these patients is an evaluation to determine that asthma is the right diagnosis. A systematic and rigorous evaluation helps to asses adequately the differential diagnoses, the comorbilities and the unusual triggers. The aim of the treatment is to achieve the best results with minimum adverse effects. New immunomodulatory therapies are needed for these patients management.


Key words: asthma, severe asthma, control.


REFERENCIAS

  1. Strek M. Difficult asthma. Proc Am Thorac Soc 2006;3:116-23.

  2. Chung K, Godard P, Adelroth E, Ayres J, et al. Difficult/therapy resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999;13:1198-208.

  3. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.

  4. Wenzel SE, Busse WW, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21.

  5. López-Viña A, Agüero-Balbín R, Aller-Álvarez JL, Bazús- González T, et al. Normativa para el asma de control difícil. Arch Bronconeumol 2005;41(9):513-23.

  6. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, et al. Severe asthma in adults: whay are the important questions? J Allergy Clin Immunol 2007;119:1337-48.

  7. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Resp Rev 1998;8:348-50.

  8. Dolan CM, Fraher KE, Bleecker ER, Borish L, et al, Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study- a large cohort of patients with severe or difficult to treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39.

  9. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13.

  10. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470-7.

  11. Fitzpatrick AM, Gaston B, Erzurum S, Teague W. Features of severe asthma in school age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006;118:1218-25.

  12. Chipps BE, Szefler SJ, Simons ER, Haselkorn T, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007;119:1156-63.

  13. Jatakanon AN, Uasuf CA, Maziak WA, Lim SA, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.

  14. Hamilton L, Torres-Lozano C, Puddicombe SM, Ritcher A, et al. Role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy 2003;33:1-8.

  15. Holgate ST, Polosa R. The mechanisms, diagnosis and management of severe asthma in adults. Lancet 2006;368:780-93.

  16. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360-8.

  17. Brasier AR, Victor S, Boetticher G, Ju H, et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008;121:30-37.

  18. Plaza-Moral V, Álvarez-Gutiérrez FJ, Casan-Clarà P, Cobos-Barroso N, et al, Guía Española para el Manejo del Asma (GEMA). Arch Bronconeumol 2003;39:S1-42.

  19. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference. Summary of recommendations. Can Respir J 1996;3:89-100.

  20. Dewey A, Bara A, Dean T, Walters EH. Dapsone as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2002;(3):CD003268.

  21. Dewey A, Bara A, Lasserson TJ, Walters EH. Colchicine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2003;(4):CD003273.

  22. Dewey A, Bara A, Lasserson TJ, Walters EH. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev 2003;(4):DC003275.

  23. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2008;(3):CD003270.

  24. Corrigan CS. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med 2002;1:47-54.

  25. Richeldi L, Ferrara G, Fabbri L, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;(4):CD002097.

  26. Evans DJ, Cullinan P, Geddes DM, Walters EH, et al. Troleandomycin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002987.

  27. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002985.

  28. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002993.

  29. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;(2):CD000391.

  30. Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis 2008;2(6):409-21.

  31. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004;(3):CD003559.

  32. Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol 2007;7:279-82.

  33. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121(1):5-10.

  34. Holgate ST, Davies DE, Lackie PM, Wilson SJ, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000;105:193-24.






>Journals >Revista Alergia México >Year 2009, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019